Flossbach Von Storch SE Grows Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Flossbach Von Storch SE boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 194,130 shares of the medical instruments supplier's stock after purchasing an additional 3,493 shares during the quarter. Flossbach Von Storch SE owned approximately 0.07% of Becton, Dickinson and Company worth $44,467,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Becton, Dickinson and Company during the first quarter valued at $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company during the first quarter valued at $29,000. REAP Financial Group LLC increased its holdings in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Picton Mahoney Asset Management increased its holdings in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after acquiring an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new position in shares of Becton, Dickinson and Company during the first quarter valued at $34,000. Institutional investors own 86.97% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BDX shares. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Piper Sandler cut Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Wells Fargo & Company cut Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Finally, Stifel Nicolaus dropped their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded up $0.80 during mid-day trading on Wednesday, reaching $175.43. The company's stock had a trading volume of 2,208,336 shares, compared to its average volume of 2,070,439. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The firm has a market capitalization of $50.28 billion, a PE ratio of 33.48, a P/E/G ratio of 1.31 and a beta of 0.25. The stock has a fifty day moving average of $172.66 and a two-hundred day moving average of $206.96. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The company's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.17 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.